SynthesisActa diabetologica2025

Beyond GLP-1: efficacy and safety of dual and triple incretin agonists in personalized type 2 diabetes care-a systematic review and network meta-analysis.

Kangling Yan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.